ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

… As Hikma Takes On A Boehringer Line

by Michael McCoy
August 3, 2015 | APPEARED IN VOLUME 93, ISSUE 31

The London-based generic drug maker Hikma Pharmaceuticals will acquire Boehringer Ingelheim’s Roxane Laboratories specialty generic drugs business for about $2.65 billion. Based in Columbus, Ohio, the business has annual sales of close to $1 billion. Hikma bought Boehringer’s generic injectable drugs businesses last year. Hikma says the latest deal will establish it as the sixth-largest player in the U.S. generics market.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment